컨퍼런스 상세안내
27th International Symposium of Yonsei Song-dang Institute for Cancer Research
신청기간: 2022년 05월 25일 (수) ~ 2022년 11월 04일 (금)
진행기간: 2022년 11월 04일 (금)
주최: 연세송당암연구센터
Program
TIME | SUBJECT | CHAIR / SPEAKER | STATUS |
---|---|---|---|
09:20 ~ 17:05 | ★27th International Symposium of Yonsei Song-dang Institute for Cancer Research★ |
|
종료 Closed |
09:20 ~ 09:25 | Opening Remarks |
Sun Young Rha, MD, PhD
(Director, Yonsei Song-dang Institute for Cancer Research, Korea)
|
|
09:25 ~ 09:30 | Welcome Address |
Eun Jig Lee, MD, PhD
(Dean, Yonsei University College of Medicine, Korea)
|
|
09:30 ~ 11:00 | Session I : Novel Therapeutic Agents |
[Chair]
Sun Young Rha, MD, PhD (Yonsei Cancer Center, Korea) Sang Joon Shin, MD, PhD (Yonsei Cancer Center, Korea) |
|
09:30 ~ 10:00 | NRG1 Fusion-Driven Cancer: New Clinically Actionable Target |
Ernesto Wasserman, MD
(Merus NV, The Netherlands)
|
|
10:00 ~ 10:20 | Precision targeting tumor cells using cancer-specific InDel mutations with CRISPR-Cas9 |
Kyungjae Myung, PhD
(Ulsan National Institute of Science and Technology, Korea)
|
|
10:20 ~ 10:40 | Discovery of novel immune modulating agent via target protein upregulation of STING |
Seung Bum Park, PhD
(Seoul National University, Korea)
|
|
10:40 ~ 11:00 | Belvarafenib, a novel type II RAF dimer inhibitor |
Seungjae Baek, MD, PhD
(Hanmi Pharmaceuticals, Kore)
|
|
11:00 ~ 11:20 | Coffee Break |
|
|
11:20 ~ 12:10 | Professor Waun Ki Hong Memorial Lecture |
[Chair] Hyun Cheol Chung, MD, PhD
(Yonsei University College of Medicine, Korea)
|
|
11:20 ~ 12:10 | Giving cancer cells a nervous breakdown (ER Stress → Apoptosis) |
Daniel D. Von Hoff, MD
(University of Arizona College of Medicine Translational Genomics Research Institute (TGen), USA)
|
|
12:10 ~ 13:00 | Lunch Break |
|
|
13:00 ~ 14:10 | Session II: Adapted Cell Therapy & Bispecific Antibody |
[Chair]
Woo Ick Jang, MD, PhD (Y-BIOLOGICS, Korea) Minkyu Jung, MD, PhD (Yonsei Cancer Center, Korea) |
|
13:00 ~ 13:20 | CAR-T cell development for dual targeting of CD19 and CD22 for Diffuse large B cell lymphoma (DLBCL) |
Sang-Jin Lee, PhD
(Research Institute of National Cancer Center, Korea)
|
|
13:20 ~ 13:50 | CLDN18.2 targeted CAR-T cell therapy in gastric cancer |
Changsong Qi, MD, PhD
(Peking University Cancer Hospital & Institute, China)
|
|
13:50 ~ 14:10 | YH32367 (ABL105), a novel HER2/4-1BB bispecific antibody for the treatment of HER2-positive tumors |
Junhwan Kim, PhD
(Yuhan Corporation, Korea)
|
|
14:10 ~ 14:20 | Coffee Break |
|
|
14:20 ~ 15:50 | Session III : Cancer Evolution and Heterogeneity |
[Chair]
Jae Kyung Roh, MD, PhD (Konyang University, Korea) Choong-kun Lee, MD, PhD (Yonsei Cancer Center, Korea) |
|
14:20 ~ 14:40 | Tracing oncogene-driven remodelling of the intestinal stem cell niche |
Bon-Kyoung Koo, PhD
(Institute for Basic Science, Korea)
|
|
14:40 ~ 15:00 | Intratumoral heterogeneity and evolution in thyroid cancer |
Seongyeol Park, MD, PhD
(GENOME INSIGHT, Korea)
|
|
15:00 ~ 15:30 | Studying the interaction between the tumor and microenvironment in gastric cancer |
Raghav Sundar, MD, PhD
(National University Cancer Institute, Singapore)
|
|
15:30 ~ 15:50 | Application of tumor organoids: intratumor heterogeneity and heterogeneous drug responses |
Ja-Lok Ku, PhD
(Seoul National University, Korea)
|
|
15:50 ~ 16:00 | Coffee Break |
|
|
16:00 ~ 17:00 | Session IV : Beyond Conventional Radiotherapy |
[Chair]
Yong Bae Kim, MD, PhD (Yonsei Cancer Center, Korea) Ik Jae Lee, MD, PhD (Yonsei Cancer Center, Korea) |
|
16:00 ~ 16:30 | Microdosimetric kinetic model for carbon-ion radiotherapy treatment planning |
Taku Inaniwa, PhD
(National Institute for Quantum Science and Technology, Japan)
|
|
16:30 ~ 17:00 | Structured Assessment of Carbon-ion Radiotherapy in treating cancers |
Eun Ho Kim, PhD
(Daegu Catholic University, Korea)
|
|
17:00 ~ 17:05 | Closing Remarks |
Sun Young Rha, MD, PhD
(Director, Yonsei Song-dang Institute for Cancer Research, Korea)
|